Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease

Jorquera, Patricia A.; Oakley, Katie; Palath, Naveen; Boyd, James G.; Tripp, Ralph A.

doi:10.3390/vaccines3040829

Cited by 22 publications

(33 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…103,104 Layer-by-layer peptide-fabricated vaccine containing alternately charged poly-L-glutamic acid and poly-L-lysine layers with RSV peptides added have been efficacious in animals. 105 A virosomal adjuvanted vaccine composed of reconstituted IFV envelope, effectively removing the core proteins and RNA, has been available for years with excellent tolerability and efficacy. 106 Several VLP vaccines based on hepatitis B virus surface antigen have been approved for viral infections, such as human papilloma virus 107 and other microbes (eg, malaria 108 ), although an IFV candidate has not progressed.…”

Section: Vaccines and Mabsmentioning

confidence: 99%

Promising approaches for the treatment and prevention of viral respiratory illnesses

Papadopoulos

Megremis

Kitsioulis

et al. 2017

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Viral respiratory tract infections are the most common human ailments, leading to enormous health and economic burden. Hundreds of viral species and subtypes have been associated with these conditions, with influenza viruses, respiratory syncytial virus, and rhinoviruses being the most frequent and with the highest burden. When considering prevention or treatment of viral respiratory tract infections, potential targets include the causative pathogens themselves but also the immune response, disease transmission, or even just the symptoms. Strategies targeting all these aspects are developing concurrently, and several novel and promising approaches are emerging. In this perspective we overview the entire range of options and highlight some of the most promising approaches, including new antiviral agents, symptomatic or immunomodulatory drugs, the re-emergence of natural remedies, and vaccines and public health policies toward prevention. Wide-scale prevention through immunization appears to be within reach for respiratory syncytial virus and promising for influenza virus, whereas additional effort is needed in regard to rhinovirus, as well as other respiratory tract viruses.

show abstract

Section: Vaccines and Mabsmentioning

confidence: 99%

Promising approaches for the treatment and prevention of viral respiratory illnesses

Papadopoulos

Megremis

Kitsioulis

et al. 2017

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

show abstract

“…CP52 (but not FI-RSV) vaccination followed by A2 challenge elicited a strong antibody response (Figures 1B,D, respectively), which was neutralizing (Figure 1E) and correlated with a statistically significant ( p ≤ 0.05) reduction in lung viral titers (Figure 1F). Despite the G protein CX3C motif having intra-strain conservation (120), it was less immunogenic as indicated by the lower anti-A2 and B1 IgG serum levels. These data show the prototypical responses associated with CP52, GA2-MP, and FI-RSV vaccination in mice (121, 122).…”

Section: Resultsmentioning

confidence: 99%

Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types

et al. 2019

View full text Add to dashboard Cite

Respiratory Syncytial Virus (RSV) causes serious respiratory tract illness and substantial morbidity and some mortality in populations at the extremes of age, i.e., infants, young children, and the elderly. To date, RSV vaccine development has been unsuccessful, a feature linked to the lack of biomarkers available to assess the safety and efficacy of RSV vaccine candidates. We examined microRNAs (miR) as potential biomarkers for different types of RSV vaccine candidates. In this study, mice were vaccinated with a live attenuated RSV candidate that lacks the small hydrophobic (SH) and attachment (G) proteins (CP52), an RSV G protein microparticle (GA2-MP) vaccine, a formalin-inactivated RSV (FI-RSV) vaccine or were mock-treated. Several immunological endpoints and miR expression profiles were determined in mouse serum and bronchoalveolar lavage (BAL) following vaccine priming, boost, and RSV challenge. We identified miRs that were linked with immunological parameters of disease and protection. We show that miRs are potential biomarkers providing valuable insights for vaccine development.

show abstract

“…Contained within the different layers different B and T cell antigens can be added allowing for the development of vaccine candidates for different disease states [173]. A malaria and a respiratory syncytial virus (RSV) vaccine candidate designed using this approach were immunogenic and capable of raising neutralizing antibodies for both either malaria or RSV respectively and the malaria candidate was able to generate cellular responses as well [174,175].…”

Section: Rationally Designed Protein Nanovaccinesmentioning

confidence: 99%

Vaccine technologies: From whole organisms to rationally designed protein assemblies

Karch¹,

Burkhard²

2016

Biochemical Pharmacology

215

185

View full text Add to dashboard Cite

Vaccines have been the single most significant advancement in public health, preventing morbidity and mortality in millions of people annually. Vaccine development has traditionally focused on whole organism vaccines, either live attenuated or inactivated vaccines. While successful for many different infectious diseases whole organisms are expensive to produce, require culture of the infectious agent, and have the potential to cause vaccine associated disease in hosts. With advancing technology and a desire to develop safe, cost effective vaccine candidates, the field began to focus on the development of recombinantly expressed antigens known as subunit vaccines. While more tolerable, subunit vaccines tend to be less immunogenic. Attempts have been made to increase immunogenicity with the addition adjuvants, either immunostimulatory molecules or an antigen delivery system that increases immune responses to vaccines. An area of extreme interest has been the application of nanotechnology to vaccine development, which allows for antigens to be expressed on a particulate delivery system. One of the most exciting examples of nanovaccines are rationally designed protein nanoparticles. These nanoparticles use some of the basic tenants of structural biology, biophysical chemistry, and vaccinology to develop protective, safe, and easily manufactured vaccines. Rationally developed nanoparticle vaccines are one of the most promising candidates for the future of vaccine development.

show abstract

Layer-By-Layer Nanoparticle Vaccines Carrying the G Protein CX3C Motif Protect against RSV Infection and Disease

Cited by 22 publications

References 41 publications

Promising approaches for the treatment and prevention of viral respiratory illnesses

Promising approaches for the treatment and prevention of viral respiratory illnesses

Determining Immune and miRNA Biomarkers Related to Respiratory Syncytial Virus (RSV) Vaccine Types

Vaccine technologies: From whole organisms to rationally designed protein assemblies

Contact Info

Product

Resources

About